source
- Kolon TissueGene cuts 37 jobs after phase 3 osteoarthritis trial failsKolon TissueGene announced it will lay off 37 employees at its Maryland headquarters, with the reductions set to take effect at the end of August. The cuts follow a phase 3 trial of the company’s…
- Third patient dies in Chinese trial of RiboX Therapeutics' experimental genetic therapyA patient with an autoimmune disease died after receiving an experimental genetic medicine from RiboX Therapeutics, a Shanghai‑based biotech startup. The death marks the third fatality reported in…